Adults with moderate to severe DPN pain were titrated to tapentadol ER @-@ mg bid during a @-week open-label period ; patients with @-point reduction in pain intensity ( @-point numerical rating scale ) at end of titration were randomized to receive placebo or tapentadol ER ( optimal dose from titration ) for @ weeks ( double-blind , fixed-dose maintenance phase ) .